Payment overview · 2025
General Payments
$967.39
60 reported records · 18 companies
Healthcare provider profile · identity verified
Mark Everett Bickers, MD
Allopathic & Osteopathic Physicians|Internal Medicine · FLOYDS KNOBS, IN · NPI 1710364179
Verified facts
What the public records show
CMS Open Payments records show Mark Everett Bickers, MD received $967.39 in general payments during 2025 across 60 reported records.
Novo Nordisk Inc accounted for 16.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 29 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Ozempic, Rybelsus, Trelegy Ellipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Vraylar by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Prolia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 137 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 134 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $162.02 | 16.8% | 12 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $159.08 | 16.4% | 13 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $105.10 | 10.9% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $64.74 | 6.7% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $62.80 | 6.5% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $58.98 | 6.1% | 4 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $55.20 | 5.7% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $50.21 | 5.2% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $49.74 | 5.1% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $37.09 | 3.8% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $31.08 | 3.2% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $23.36 | 2.4% | 1 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $21.42 | 2.2% | 1 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $19.54 | 2.0% | 1 | 2025 |
| Corium, LLC | Unresolved — no canonical attribution shown | $18.97 | 2.0% | 1 | 2025 |
| Cranial Technologies, Inc | Unresolved — no canonical attribution shown | $17.14 | 1.8% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.15 | 1.7% | 1 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $14.77 | 1.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $929.69 | 58 |
| Education | $37.70 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $150.93 | 7 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $128.13 | 9 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $128.13 | 9 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $123.09 | 10 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $123.09 | 10 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $58.98 | 4 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $55.20 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $49.74 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $46.96 | 3 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $35.99 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $33.89 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $31.50 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $31.08 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $29.10 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $23.40 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $23.36 | 1 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $21.42 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $21.42 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $21.11 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $21.11 | 1 | 2025 |
Source payment records
|
|||||
| Jornay PM Normalized: jornay pm |
Drug | Collegium Pharmaceutical, Inc. | $19.54 | 1 | 2025 |
Source payment records
|
|||||
| Azstarys Normalized: azstarys |
Drug | Corium, LLC | $18.97 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $18.91 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $18.91 | 1 | 2025 |
Source payment records
|
|||||
| Doc Band Normalized: doc band |
Device | Cranial Technologies, Inc | $17.14 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $16.15 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $15.46 | 1 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $14.77 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $13.69 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 134 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 49 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 137 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 33 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
49 | 11 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
49 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
137 | 23 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
134 | 30 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 749 | 213 |
| Levothyroxine Sodium | Levothyroxine Sodium | 400 | 96 |
| Lisinopril | Lisinopril | 338 | 102 |
| Losartan Potassium | Losartan Potassium | 336 | 89 |
| Metoprolol Succinate | Metoprolol Succinate | 334 | 85 |
| Gabapentin | Gabapentin | 327 | 83 |
| Amlodipine Besylate | Amlodipine Besylate | 319 | 94 |
| Pantoprazole Sodium | Pantoprazole Sodium | 280 | 85 |
| Trazodone Hcl | Trazodone Hcl | 259 | 61 |
| Meloxicam | Meloxicam | 232 | 75 |
| Omeprazole | Omeprazole | 216 | 53 |
| Tamsulosin Hcl | Tamsulosin Hcl | 214 | 55 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 178 | 40 |
| Hydrochlorothiazide | Hydrochlorothiazide | 169 | 49 |
| Furosemide | Furosemide | 158 | 42 |
| Metoprolol Tartrate | Metoprolol Tartrate | 151 | 38 |
| Metformin Hcl | Metformin Hcl | 150 | 43 |
| Pravastatin Sodium | Pravastatin Sodium | 138 | 36 |
| Ozempic | Semaglutide | 137 | 23 |
| Eliquis | Apixaban | 134 | 30 |
| Allopurinol | Allopurinol | 129 | 37 |
| Alendronate Sodium | Alendronate Sodium | 128 | 44 |
| Escitalopram Oxalate | Escitalopram Oxalate | 124 | 34 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 120 | 34 |
| Clonazepam | Clonazepam | 113 | 28 |
| Diclofenac Sodium | Diclofenac Sodium | 113 | 26 |
| Hydralazine Hcl | Hydralazine Hcl | 111 | 28 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 110 | 38 |
| Montelukast Sodium | Montelukast Sodium | 110 | 32 |
| Prednisone | Prednisone | 105 | 76 |
| Potassium Chloride | Potassium Chloride | 104 | 30 |
| Celecoxib | Celecoxib | 100 | 27 |
| Simvastatin | Simvastatin | 100 | 30 |
| Glimepiride | Glimepiride | 98 | 30 |
| Fluticasone Propionate | Fluticasone Propionate | 95 | 43 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 95 | 29 |
| Famotidine | Famotidine | 90 | 30 |
| Finasteride | Finasteride | 90 | 24 |
| Citalopram Hbr | Citalopram Hydrobromide | 89 | 19 |
| Alprazolam | Alprazolam | 86 | 19 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 82 | 26 |
| Pregabalin | Pregabalin | 78 | 21 |
| Carvedilol | Carvedilol | 77 | 21 |
| Cephalexin | Cephalexin | 74 | 51 |
| Tramadol Hcl | Tramadol Hcl | 72 | 24 |
| Clopidogrel | Clopidogrel Bisulfate | 70 | 22 |
| Zolpidem Tartrate | Zolpidem Tartrate | 67 | 27 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 66 | 21 |
| Quetiapine Fumarate | Quetiapine Fumarate | 64 | 19 |
| Sertraline Hcl | Sertraline Hcl | 60 | 15 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 58 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 57 | 17 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 56 | 11 |
| Atenolol | Atenolol | 55 | 18 |
| Spironolactone | Spironolactone | 54 | 16 |
| Donepezil Hcl | Donepezil Hcl | 53 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 53 | 13 |
| Ondansetron Odt | Ondansetron | 50 | 21 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 49 | 14 |
| Jardiance | Empagliflozin | 49 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 49 | 19 |
| Temazepam | Temazepam | 48 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 48 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 48 | 11 |
| Warfarin Sodium | Warfarin Sodium | 47 | 14 |
| Amitriptyline Hcl | Amitriptyline Hcl | 46 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 45 | 15 |
| Primidone | Primidone | 42 | suppressed |
| Xarelto | Rivaroxaban | 41 | 12 |
| Bupropion Xl | Bupropion Hcl | 40 | 13 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 40 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 39 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 38 | 13 |
| Azithromycin | Azithromycin | 38 | 33 |
| Colestipol Hcl | Colestipol Hcl | 37 | 16 |
| Linzess | Linaclotide | 37 | suppressed |
| Gemtesa | Vibegron | 36 | suppressed |
| Ibuprofen | Ibuprofen | 36 | 14 |
| Mirtazapine | Mirtazapine | 36 | 13 |
| Lorazepam | Lorazepam | 35 | suppressed |
| Rybelsus | Semaglutide | 35 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 33 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 33 | suppressed |
| Vraylar | Cariprazine Hcl | 33 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 32 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 30 | 11 |
| Synthroid | Levothyroxine Sodium | 30 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 29 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 28 | 11 |
| Diazepam | Diazepam | 28 | suppressed |
| Methylprednisolone | Methylprednisolone | 28 | 26 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 28 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 27 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 27 | 11 |
| Testosterone Cypionate | Testosterone Cypionate | 27 | suppressed |
| Topiramate | Topiramate | 27 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 26 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 26 | 14 |
| Ezetimibe | Ezetimibe | 26 | suppressed |
| Hydrocortisone | Hydrocortisone | 26 | 15 |
| Premarin | Estrogens, Conjugated | 26 | suppressed |
| Verapamil Er | Verapamil Hcl | 26 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 25 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 25 | 18 |
| Trintellix | Vortioxetine Hydrobromide | 24 | suppressed |
| Ciclopirox | Ciclopirox | 23 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 22 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 21 | suppressed |
| Ibu | Ibuprofen | 21 | suppressed |
| Januvia | Sitagliptin Phosphate | 21 | suppressed |
| Memantine Hcl | Memantine Hcl | 21 | suppressed |
| Gemfibrozil | Gemfibrozil | 20 | suppressed |
| Nifedipine Er | Nifedipine | 20 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 20 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 20 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 19 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 19 | suppressed |
| Klor-Con M20 | Potassium Chloride | 19 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 18 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 18 | suppressed |
| Fentanyl | Fentanyl | 18 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 18 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 18 | suppressed |
| Trulicity | Dulaglutide | 18 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 17 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 17 | suppressed |
| Fluconazole | Fluconazole | 17 | suppressed |
| Lidocaine | Lidocaine | 17 | suppressed |
| Prolia | Denosumab | 17 | suppressed |
| Roflumilast | Roflumilast | 17 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | suppressed |
| Digoxin | Digoxin | 16 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 16 | suppressed |
| Lovastatin | Lovastatin | 16 | suppressed |
| Lubiprostone | Lubiprostone | 16 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 16 | suppressed |
| Sotalol | Sotalol Hcl | 16 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 15 | suppressed |
| Irbesartan | Irbesartan | 15 | suppressed |
| Naproxen | Naproxen | 15 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 15 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 15 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 15 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Baclofen | Baclofen | 14 | suppressed |
| Valsartan | Valsartan | 14 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | 13 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 13 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 13 | suppressed |
| Lamotrigine | Lamotrigine | 13 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 13 | suppressed |
| Loperamide | Loperamide Hcl | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 13 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 13 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Clotrimazole | Clotrimazole | 12 | suppressed |
| Methocarbamol | Methocarbamol | 12 | suppressed |
| Calcipotriene | Calcipotriene | 11 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $967.39 · 60 records | Novo Nordisk Inc | Azstarys, BREZTRI, CAPLYTA, Cologuard Collection Kit, Doc Band, ELIQUIS, EVENITY, FARXIGA, Fluad, Flucelvax, GVOKE HYPOPEN, JARDIANCE, Jornay PM, Kerendia, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, QULIPTA, REPATHA, Rybelsus, TRELEGY ELLIPTA, Tymlos, UBRELVY, VRAYLAR, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error